Dr Helmut Haning has recently joined the management of Ksilink as COO, complementing the team with a longstanding experience in pharmaceutical drug discovery. He brings to the company a wealth of knowledge and expertise in drug discovery, strategy and operational excellence that will benefit in its future path.
Helmut is also Operating Partner at ARCHIMED, the world leading healthcare Private Equity fund.
In addition, he serves as SVP, Head of Drug Discovery for Metabiopharma in the field of rare genetic and autoimmune diseases.
Helmut started his career as an organic chemist. He joined Bayer, a German pharmaceutical company, in 1995 and subsequently assumed different roles of growing impact and responsibility in the company, retiring as Global Head of Medicinal Chemistry. He is the inventor of a marketed drug and several clinical candidates in different indications. He also build built an early partnering function covering all academic cooperations and early licensing activities. With Metabiopharma, he was successful in identifying a preclinical candidate for a rare genetic disease.